Revenue declined year over year, including a revision of the full-year outlook. Indicates segment contributions and improvements in cost structure. Contributions from AI-related and exosome-related businesses and others varied versus the previous period.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4880","jir_company_name":"CellSource Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-09-08","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/09\/4880-20260908-06.pdf","jir_short_summary":"Revenue declined year over year, including a revision of the full-year outlook. Indicates segment contributions and improvements in cost structure. Contributions from AI-related and exosome-related businesses and others varied versus the previous period.","jir_summary":"### \u696d\u7e3e\u306e\u6982\u8981\nFor the third quarter of the fiscal year ending October 2026, revenue was flat to slightly down versus the previous period, while operating income improved significantly. Key drivers are cost control and productivity improvements. Contributions from certain segments, such as self-funded orthopedic care and exosome-related businesses, varied versus the prior period. The company\u2019s overall revenue mix remains diversified, with cosmetics sales appearing as a headwind.\n\n### \u4eca\u5f8c\u306e\u898b\u901a\u3057\u3068\u8cc7\u672c\u653f\u7b56\nThe outlook includes potential revisions to full-year earnings; explanations of key measures and progress, particularly in contract processing services, medical device sales, and PAJUU, outlining growth strategies. Ongoing progress in new businesses and cost-reduction efforts are expected to support profit improvement in the next period.","jir_financial_highlights":"Revenue: 2,557 (YoY -9.2%)\nOperating income: 179 (YoY +45.3%)\nGross profit margin: 59.6% (+1.3pp)","jir_category":"","jir_hashtags":"#Earnings","jir_key_figures":"Net sales: 2,557 million yen (YoY -9.2%)\nOperating income: 179 million yen (YoY +45.3%)\nGross profit margin: 58.9%\u201359.6% (approximately +1.3pt)","jir_meta_title":"\u3010\u30bb\u30eb\u30bd\u30fc\u30b9\u30112026\u5e7410\u6708\u671f \u7b2c3\u56db\u534a\u671f\u6c7a\u7b97\uff5c\u58f2\u4e0a\u9ad82,557\u767e\u4e07\u5186\uff08\u524d\u5e74\u540c\u671f\u6bd4-9.2%\uff09","jir_meta_description":"\u30bb\u30eb\u30bd\u30fc\u30b9\u306e2026\u5e7410\u6708\u671f\u7b2c3\u56db\u534a\u671f\u6c7a\u7b97\u306e\u8981\u70b9\u3002\u58f2\u4e0a\u9ad8\u3001\u55b6\u696d\u5229\u76ca\u3001\u58f2\u4e0a\u7dcf\u5229\u76ca\u7387\u3001\u30bb\u30b0\u30e1\u30f3\u30c8\u52d5\u5411\u3001\u4eca\u5f8c\u306e\u898b\u901a\u3057\u3001\u4e3b\u8981\u65bd\u7b56\u306e\u9032\u6357\u3092\u8981\u7d04\u3002","jir_og_title":"\u30bb\u30eb\u30bd\u30fc\u30b9 \u7b2c3\u56db\u534a\u671f\u6c7a\u7b97\u306e\u8981\u70b9\uff5c2026\u5e7410\u6708\u671f","jir_og_description":"\u30bb\u30eb\u30bd\u30fc\u30b9\u306e2026\u5e7410\u6708\u671f\u7b2c3\u56db\u534a\u671f\u6c7a\u7b97\u3002\u58f2\u4e0a\u9ad8\u30fb\u55b6\u696d\u5229\u76ca\u306e\u52d5\u5411\u3068\u4eca\u5f8c\u306e\u898b\u901a\u3057\u3092\u8981\u7d04\u3002","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":59237,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"general_ir","footnotes":""},"sector":[],"importance":[],"class_list":["post-111534","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n